285 results
Page 3 of 15
8-K
8ux2fw4wq0o jchjese
19 Aug 20
Mateon Therapeutics Selects IQVIA for its Randomized, Controlled, Multi-Center Clinical Study to Test OT-101 as a Treatment for COVID-19 Patients
6:20am
8-K
EX-10.6
8m7ewu9zrc6mzwt
13 Aug 20
Entry into a Material Definitive Agreement
5:15pm
8-K
EX-10.1
gao15h2 yuu
13 Aug 20
Entry into a Material Definitive Agreement
5:15pm
8-K
EX-10.1
pxn gwqmnmz
3 Aug 20
Entry into a Material Definitive Agreement
8:43am
8-K
EX-10.3
k0ip9k
3 Aug 20
Entry into a Material Definitive Agreement
8:43am
8-K
z5l8c4jq7wdl9tqx3
3 Aug 20
Entry into a Material Definitive Agreement
8:43am
8-K
EX-10.4
aeygx7 ca720pm3d5f
3 Aug 20
Entry into a Material Definitive Agreement
8:43am
8-K
EX-10.2
pl1r7q0i1wjls
3 Aug 20
Entry into a Material Definitive Agreement
8:43am
8-K
EX-10.1
dnfhe
29 Jul 20
Mateon Therapeutics Closes $2.0 Million Financing
5:14pm
8-K
EX-10.6
yyuooepw
29 Jul 20
Mateon Therapeutics Closes $2.0 Million Financing
5:14pm
8-K
EX-10.2
cj5 qmvrx
16 Jun 20
Mateon Announces Achievement of Milestone Under Licensing of OT-101/IL-2 Combination to Autotelic Bio
6:58am
8-K
EX-99.1
4d407 tw17o33
2 Dec 19
Other Events
9:45am
8-K
EX-99.1
q6330gna1rja7c62m65
10 Sep 19
Mateon Partners with WideTrial for Data-Generating Expanded Access Programs in Cancer
9:15am
8-K
EX-10.1
2m47rli336xmkmgqbvn6
10 Sep 19
Mateon Partners with WideTrial for Data-Generating Expanded Access Programs in Cancer
9:15am
8-K
8gdy6phanuwj
10 Sep 19
Mateon Partners with WideTrial for Data-Generating Expanded Access Programs in Cancer
9:15am
8-K
EX-10.2
xv5os
10 Sep 19
Mateon Partners with WideTrial for Data-Generating Expanded Access Programs in Cancer
9:15am